In September 2025, Virginia Attorney General Jason Miyares announced an investigation into insulin manufacturers and pharmacy benefit managers for alleged price inflation under the Virginia Consumer Protection Act. In this column for Law360, AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny, Chuck Slemp analyzes how this investigation reflects a broader national trend of state attorneys general targeting drug pricing practices using consumer protection and antitrust laws to tackle opaque pricing structures and drive healthcare affordability. Companies in the pharmaceutical supply chain should anticipate heightened scrutiny and potential settlements. Expect more multistate coordination, aggressive litigation, and structural reforms in 2026.

Read more here.